Money moving to APH [LSE] , excellent profitable healthcare company |
Wonder how many Fusion Pharm shareholders were relatively new and benefitted from the 97% premium to 18th March close!
Bound to have been plenty of insider dealing stateside, probably in "Options" to leverage the benefit.
Under the terms of the definitive agreement, AstraZeneca, through a subsidiary, will acquire all of Fusion's outstanding shares pursuant to a plan of arrangement for a price of $21.00 per share in cash at closing plus a non-transferable contingent value right of $3.00 per share in cash payable upon the achievement of a specified regulatory milestone. The upfront cash portion of the consideration represents a transaction value of approximately $2bn, a 97% premium to Fusion's closing market price of $10.64 on 18th March 2024 and an 85% premium to the 30-day volume-weighted average price (VWAP) of $11.37 before this announcement. |
A billion dollar deal last week and a two billion dollar deal today….Mr Soriot is investing for the future….that is where the divi increase is being diverted to. |
They bought one in early phase development in November:
hxxps://www.astrazeneca.com/media-centre/press-releases/2023/agreement-with-eccogene-for-clinical-stage-glp-1ra.html |
It's a shame Astra did not have the fat buster drug, Novo Nordisk and EJ Lily gone through the roof. |
Astra has an IR day in May where they are expected to try to talk up their longer term growth potential |
Money moving to APH , excellent growth health care company |
philanderer - a suggestion
The link does work if you delete everything after "html" - otherwise it seems to stretch the page. |
"The £135m man: That's how much Pascal Soriot has been paid in 12 years at AstraZeneca... with more to come" |
Berenberg cuts AstraZeneca price target to 12,000 (12,500) pence - 'buy' |
MARKET REPORT: Lung cancer drug gives AstraZeneca a shot in arm |
Hopefully the US investors will get this moving up tomorrow |
#987. Novo will need to use its new cash flows to diversify. |
Today's news good for the company and good for patients. |
Novo Nordisk the pharma to be in and Glaxo looking good. |
Market report
"...AstraZeneca shares came into the week on a three-day losing streak, including a more than 6% slide on the day it released annual results.
"‘We think this presents a compelling entry point for a best-in-class company,’ analysts at Barclays said on Monday, however."
sharesmagazine.co.uk |
Don't tell me you sold these to buy APH as well! If APH are so good you should follow your own advice and put all your eggs in that creaky basket. |
Ex div on the 22nd, may pick up some before then. |
24 month low for the shareprice.
Chartwise, support at 8300p |
Blackhorse. No it isn't. Grow up. |
Money moving to APH |
Quite a spread of views!
It is important to bear in mind what a commentator's price target means: it is not 'current fair value', but (unless otherwise stated) a price which the commentator at present believes will be hit at some time within the following 12 months, and not necessarily sustained thereafter, still less that there will not be further rises /falls from the price at the date on which the target was stated before that figure is hit, if indeed it is hit. |
Stifel cuts AstraZeneca price target to 12,000 (12,550) pence - 'buy'
Barclays cuts AstraZeneca price target to 12,500 (13,500) pence - 'overweigh
UBS cuts AstraZeneca price target to 9,900 (10,700) pence - 'sell' |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
